NervGen Pharma Corp. Common stock
NervGen Pharma Corp. Common stock
- Market cap
- $198.55M
Your view on NGEN
Overview
What the company does, where it operates, and who runs it.
About NervGen Pharma Corp. Common stock
- Industry
- Not available
- Sector
- Not available
- CEO
- Not available
- Headquarters
- CA
- Industry
- Not available
- Sector
- Not available
- CEO
- Not available
- Headquarters
- CA
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for NervGen Pharma Corp. Common stock. Starting points for NervGen Pharma Corp. Common stock: EPS -$0.65, beta 0.78. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for NervGen Pharma Corp. Common stock. Trailing twelve-month EPS for NervGen Pharma Corp. Common stock stands at -$0.65. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Targets, low to high
Analyst ratings
1 rating- Strong Buy0
- Buy1
- Hold0
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −CAD 0.08 | −CAD 0.09 | −CAD 0.13 | −CAD 0.35 |
| Lowest estimate | −CAD 0.08 | −CAD 0.10 | −CAD 0.27 | −CAD 0.71 |
| Highest estimate | −CAD 0.08 | −CAD 0.08 | CAD 0.00 | CAD 0.00 |
| Number of analysts | 2 | 3 | 2 | 2 |
| A year ago | −CAD 0.261 | −CAD 0.261 | −CAD 0.611 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | CAD 0.00 | CAD 0.00 | CAD 0.00 | CAD 0.00 |
| Lowest estimate | CAD 0.00 | CAD 0.00 | CAD 0.00 | CAD 0.00 |
| Highest estimate | CAD 0.00 | CAD 0.00 | CAD 0.00 | CAD 0.00 |
| Number of analysts | 0 | 0 | 0 | 0 |
| A year ago | CAD 0.00 | CAD 0.00 | CAD 0.00 | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for NervGen Pharma Corp. Common stock. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| GWXState Street SPDR S&P International Small Cap ETF | $882M in assets | 0.01% | |
| IBRNiShares Neuroscience and Healthcare ETF | $9M in assets | 0.27% | |
Largest holders first, then the funds most concentrated in NGEN.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold NervGen Pharma Corp. Common stock, and how their positions are changing. At a $198.6M market value, institutional positions materially move NervGen Pharma Corp. Common stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by NervGen Pharma Corp. Common stock executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for NervGen Pharma Corp. Common stock. Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of NervGen Pharma Corp. Common stock.